26.08

0.31% +0.08

Dyne Therapeutics Inc (DYN)

Overview News Price History Option Chain Financials Why DYN Down? Discussions Forecast

Dyne Therapeutics Inc stock is currently priced at $26.08, with a 24-hour trading volume of 749.96K. It has seen a +0.31% increased in the last 24 hours and a -9.32% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $25.97 pivot point. If it approaches the $27.14 resistance level, significant changes may occur.

Previous Close:

$26.00

Open:

$26

24h Volume:

749.96K

Market Cap:

$2.28B

Revenue:

Net Income/Loss:

$-235.94M

P/E Ratio:

-7.6706

EPS:

-3.4

Net Cash Flow:

$-188.89M

1W Performance:

+5.46%

1M Performance:

-9.32%

6M Performance:

+216.89%

1Y Performance:

+116.07%

1D Range:

$25.87

$27.31

52W Range:

$6.40

$30.27

Dyne Therapeutics Inc Stock (DYN) Company Profile

Name

Dyne Therapeutics Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

781 786 8230

Address

830 Winter Street, Waltham

Employee

Twitter

Next Earnings Date

2024-05-09

Latest SEC Filings

DYN's Discussions on Twitter

Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy
Feb-15-23	Initiated	Oppenheimer	Outperform
Jan-26-23	Initiated	Guggenheim	Buy
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Outperform
Oct-12-20	Initiated	JP Morgan	Overweight
Oct-12-20	Initiated	Jefferies	Buy
Oct-12-20	Initiated	Piper Sandler	Overweight
Oct-12-20	Initiated	Stifel	Buy

View All

Dyne Therapeutics Inc Stock (DYN) Latest News

Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire Inc.

Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer

GlobeNewswire Inc.

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday

Benzinga

Dyne Therapeutics Announces CEO Transition

GlobeNewswire Inc.

Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge

Benzinga

Dyne Therapeutics Inc Stock (DYN) Financials Data

Dyne Therapeutics Inc (DYN) Net Income 2024

DYN net income (TTM) was -$235.94 million for the quarter ending December 31, 2023, a -40.36% decrease year-over-year.

Dyne Therapeutics Inc (DYN) Cash Flow 2024

DYN recorded a free cash flow (TTM) of -$188.89 million for the quarter ending December 31, 2023, a -20.53% decrease year-over-year.

Dyne Therapeutics Inc (DYN) Earnings per Share 2024

DYN earnings per share (TTM) was -$3.94 for the quarter ending December 31, 2023, a -21.60% decline year-over-year.

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.